VSTM Key Statistics, Chart & Performance
The current stock price of VSTM is 8.64 USD. In the past month the price decreased by -5.57%. In the past year, price increased by 106.21%.
VSTM Latest News, Press Relases and Analysis
VSTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.67 | 395.31B | ||
| AMGN | AMGEN INC | 14.94 | 175.94B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 147.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.21 | 115.43B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.58 | 78.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767 | 51.68B | ||
| INSM | INSMED INC | N/A | 42.80B | ||
| NTRA | NATERA INC | N/A | 31.38B | ||
| BIIB | BIOGEN INC | 10.24 | 25.16B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.95 | 21.53B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.11 | 19.05B |
Related stock screener links
About VSTM
Company Profile
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Company Info
VERASTEM INC
117 Kendrick Street, Suite 500
Needham MASSACHUSETTS 02494 US
CEO: Brian M. Stuglik
Employees: 78
Phone: 17812924200
VERASTEM INC / VSTM FAQ
Can you describe the business of VERASTEM INC?
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2011-11-08. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
What is the stock price of VERASTEM INC today?
The current stock price of VSTM is 8.64 USD. The price decreased by -6.8% in the last trading session.
Does VSTM stock pay dividends?
VSTM does not pay a dividend.
What is the ChartMill rating of VERASTEM INC stock?
VSTM has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for VSTM stock?
VERASTEM INC (VSTM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.86).
Can you provide the upcoming earnings date for VERASTEM INC?
VERASTEM INC (VSTM) will report earnings on 2026-03-18, after the market close.
Can you provide the ownership details for VSTM stock?
You can find the ownership structure of VERASTEM INC (VSTM) on the Ownership tab.
VSTM Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to VSTM. When comparing the yearly performance of all stocks, VSTM is one of the better performing stocks in the market, outperforming 93.51% of all stocks.
VSTM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VSTM. VSTM may be in some trouble as it scores bad on both profitability and health.
VSTM Financial Highlights
Over the last trailing twelve months VSTM reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS decreased by -21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VSTM Forecast & Estimates
15 analysts have analysed VSTM and the average price target is 16.32 USD. This implies a price increase of 88.89% is expected in the next year compared to the current price of 8.64.
For the next year, analysts expect an EPS growth of 8.16% and a revenue growth 210.11% for VSTM